MX2015011462A - Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. - Google Patents

Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.

Info

Publication number
MX2015011462A
MX2015011462A MX2015011462A MX2015011462A MX2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A
Authority
MX
Mexico
Prior art keywords
cholestosome
loaded
present
patient
molecules
Prior art date
Application number
MX2015011462A
Other languages
English (en)
Inventor
Jerome J Schentag
Mary P Mccourt
Lawrence Mielnicki
Julie Hughes
Original Assignee
Jerome J Schentag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581747&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015011462(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jerome J Schentag filed Critical Jerome J Schentag
Publication of MX2015011462A publication Critical patent/MX2015011462A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

La presente invención está dirigida a una nanopartícula de éster de colesterilo portadora de carga, con un compartimento hueco (cholestosome: colestosoma), que esencialmente consiste en al menos un éster de colesterilo no iónico y una o más moléculas activas encapsuladas, el cual no puede pasar apreciablemente a través de una membrana enterocítica en ausencia de la molécula que se carga en el colestosoma, el colestosoma tiene una superficie neutra y la capacidad de pasar a los enterocitos como lo hacen los lípidos nutrientes absorbidos por vía oral que utilizan las vías celulares para llegar al aparato de Golgi. Según la presente invención, los nuevos colestosomas portadores de carga según la presente invención, tienen la capacidad de depositar moléculas activas dentro de las células de un paciente o de un individuo y realizar tratamiento o diagnóstico en el paciente o el individuo.
MX2015011462A 2013-03-14 2014-03-14 Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. MX2015011462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783003P 2013-03-14 2013-03-14
PCT/US2014/027761 WO2014152795A2 (en) 2013-03-14 2014-03-14 Cholestosome vesicles for incorporation of molecules into chylomicrons

Publications (1)

Publication Number Publication Date
MX2015011462A true MX2015011462A (es) 2016-05-31

Family

ID=51581747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011462A MX2015011462A (es) 2013-03-14 2014-03-14 Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.

Country Status (11)

Country Link
US (5) US9693968B2 (es)
EP (1) EP2970369B1 (es)
JP (2) JP2016513712A (es)
CN (1) CN105164143B (es)
AU (1) AU2014236559B2 (es)
BR (1) BR112015022936A2 (es)
CA (1) CA2905108C (es)
HK (1) HK1212354A1 (es)
IL (1) IL241501B (es)
MX (1) MX2015011462A (es)
WO (1) WO2014152795A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
US9693968B2 (en) * 2013-03-14 2017-07-04 Jerome J. Schentag Cholestosome vesicles for incorporation of molecules into chylomicrons
JP6697384B2 (ja) 2013-07-25 2020-05-20 イグジキュア, インコーポレーテッドExicure, Inc. 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
US10260067B2 (en) 2014-10-01 2019-04-16 The Brigham And Women's Hospital, Inc. Enhancing dermal wound healing by downregulating microRNA-26a
ES2574615B1 (es) * 2014-12-19 2017-07-24 Biopraxis Research Aie Nanopartícula lipídica de tobramicina
CN108697768B (zh) 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经***病状和神经退行性病状的治疗方法
CN105797132A (zh) * 2016-05-03 2016-07-27 滨州医学院 沙奎拉韦的医药新用途
US20190175515A1 (en) * 2016-08-23 2019-06-13 Jerome J. Schentag Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
CN107260681A (zh) * 2017-08-04 2017-10-20 济南维瑞医药科技开发有限公司 一种磷酸特地唑胺脂质体的制备方法及其应用
US11504325B2 (en) 2017-08-09 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Micelles and vesicles for the delivery of glycopeptides
CN111518770B (zh) 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
BR112020014596A2 (pt) 2018-01-23 2020-12-08 Gila Therapeutics, Inc. Formulações, composições e métodos farmacêuticos de peptídeo yy
CA3128398A1 (en) * 2018-02-01 2019-08-08 The Royal Institution For The Advancement Of Learning / Mcgill University Formulations for improving the delivery of hydrophobic agents
KR20210149157A (ko) * 2019-05-14 2021-12-08 파모사 바이오팜 인코포레이티드 약산성 약물의 약제학적 조성물 및 투여 방법
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN110638788A (zh) * 2019-10-25 2020-01-03 广州医科大学 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送***及应用
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
JP2023543037A (ja) * 2020-09-25 2023-10-12 アルゴリズム サイエンシズ，インコーポレイテッド 血管拡張剤送達のための組成物及び方法
WO2023112974A1 (ja) * 2021-12-14 2023-06-22 シード医療製薬株式会社 海藻抽出物を含む高血圧症改善剤並びに同高血圧症改善剤を含む機能性食品、医薬部外品及び医薬品
CN114470186B (zh) * 2022-02-17 2023-10-20 唐颐控股(深圳)有限公司 一种可吸入式纳米新冠疫苗的制备方法
WO2023178425A1 (en) 2022-03-23 2023-09-28 Nanovation Therapeutics Inc. High sterol-containing lipid nanoparticles

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
DE68901733T2 (de) 1988-03-04 1993-03-25 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1992003123A1 (en) 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
PT937456E (pt) 1998-02-23 2004-10-29 Cilag Ag Int Dispersao lipossomal de eritropoietina
CA2483505A1 (en) 2002-04-26 2003-11-06 Anges Mg, Inc. Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
EP3100719A3 (en) * 2002-05-15 2017-02-22 California Pacific Medical Center Delivery of nucleic acid-like compounds
WO2004089327A1 (en) 2003-04-11 2004-10-21 Coreana Cosmetics Co., Ltd. Medicinal cosmetical composition with areca catechu seed extract
WO2004098564A2 (en) 2003-05-02 2004-11-18 The Board Of Trustees Of The University Of Illinois Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
JP2007501850A (ja) 2003-05-09 2007-02-01 ノボソム アーゲー 作用物質のデリバリーのための注射可能なリポソーム式デポー製剤
CN101031287A (zh) * 2004-03-02 2007-09-05 麻省理工学院 纳米细胞药物递送***
WO2007021822A2 (en) 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
US20100080773A1 (en) * 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
JP5336500B2 (ja) * 2007-10-17 2013-11-06 韓国科学技術院 核酸伝達用低密度リポタンパク質類似（ＬＤＬ−ｌｉｋｅ）陽イオン性ナノ粒子、その製造方法、及びこれを用いた核酸の伝達方法
US20110046053A1 (en) * 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
ES2680222T3 (es) * 2008-05-22 2018-09-05 H. Lundbeck A/S Modulación de los receptores con dominio Vps10p para el tratamiento de la enfermedad cardiovascular
US9757346B2 (en) 2008-09-03 2017-09-12 Volant Holdings Gmbh Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes)
WO2010027498A2 (en) 2008-09-03 2010-03-11 New Science Holdings, Llc Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
JP2009143963A (ja) 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
AU2011227686B2 (en) 2010-03-19 2014-12-04 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20110268653A1 (en) 2010-04-16 2011-11-03 The Board Of Regents Of The University Of Texas System Compositions and Methods Related to Acid Stable Lipid Nanospheres
US8355188B2 (en) 2010-07-27 2013-01-15 Foxlink Image Technology Co., Ltd. Document guiding mechanism
KR20200006177A (ko) 2011-03-02 2020-01-17 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
AU2012253373A1 (en) * 2011-05-11 2013-11-28 Nanovalent Pharmaceuticals, Inc. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor
US9693969B2 (en) 2012-01-02 2017-07-04 Andrew L. SKIGEN Mucous membrane active agent application
CA2868362C (en) 2012-03-29 2018-07-31 Jerome Schentag Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
US9693968B2 (en) 2013-03-14 2017-07-04 Jerome J. Schentag Cholestosome vesicles for incorporation of molecules into chylomicrons
SG11201507061XA (en) 2013-03-15 2015-10-29 Alltech Inc Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
US20190175515A1 (en) 2016-08-23 2019-06-13 Jerome J. Schentag Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells

Also Published As

Publication number Publication date
US11633364B2 (en) 2023-04-25
AU2014236559A1 (en) 2018-05-24
US11052052B2 (en) 2021-07-06
BR112015022936A2 (pt) 2017-07-18
US9693968B2 (en) 2017-07-04
CA2905108A1 (en) 2014-09-25
US20220040116A1 (en) 2022-02-10
US20180055780A1 (en) 2018-03-01
IL241501A0 (en) 2015-11-30
JP6688408B2 (ja) 2020-04-28
JP2016513712A (ja) 2016-05-16
EP2970369A2 (en) 2016-01-20
US12005146B2 (en) 2024-06-11
JP2019070031A (ja) 2019-05-09
WO2014152795A2 (en) 2014-09-25
CA2905108C (en) 2021-12-07
EP2970369B1 (en) 2023-11-22
CN105164143B (zh) 2019-02-19
CN105164143A (zh) 2015-12-16
US10369114B2 (en) 2019-08-06
IL241501B (en) 2020-05-31
EP2970369A4 (en) 2016-10-12
HK1212354A1 (en) 2016-06-10
WO2014152795A3 (en) 2014-11-27
AU2014236559B2 (en) 2020-03-12
US20200069598A1 (en) 2020-03-05
US20160030361A1 (en) 2016-02-04
US20230277471A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
MX2015011462A (es) Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
WO2012083185A8 (en) Peptide-based in vivo sirna delivery system
WO2014170389A8 (en) Enhanced adoptive cell therapy
WO2012122544A3 (en) Protein nanoparticle dispersions
MX2016006988A (es) Nuevos peptidos hidrofobos ultracortos que se autoensamblan en hidrogeles nanofibrosos y sus usos.
WO2015095624A3 (en) Drug mixing and delivery system and method
WO2014028493A3 (en) Exosomes and micro-ribonucleic acids for tissue regeneration
BR112014032897A2 (pt) métodos e aparelho para formar baterias impressas em dispositivos oftálmicos
MX2013001636A (es) Composiciones y metodos para el tratamiento de taupatias
WO2013084000A3 (en) Exosomes for delivery of biotherapeutics
WO2015059180A3 (en) Upconverting vesicles and uses
BR112015003794A2 (pt) partículas funcionalizadas do grupo iva e métodos de uso destas
AU2018205186B2 (en) Angiotensin in treating brain conditions
WO2012116073A3 (en) Amphiphilic dendron-coils, micelles thereof and uses
WO2013090523A3 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
WO2013136189A3 (en) Methods and materials for treatment of pompe's disease
MX2014002062A (es) Nanoparticulas de peptido y usos de las mismas.
MX359004B (es) Método para la fabricación de células madre que tienen tamaño apropiado para administración intravascular.
WO2014138315A8 (en) Heparanase expression in human t lymphocytes
WO2013111012A3 (en) Methods and compositions for therapeutic agents
WO2012040331A3 (en) Multistage nanoparticles
WO2014113704A3 (en) Enhanced differentiation of mesenchymal stem cells
WO2010086838A3 (en) Non-ad5 adenoviral vectors and methods and uses related thereto
WO2013175379A3 (en) Cellulose capsules
EP3377622A4 (en) TARGETED DISTRIBUTION OF BIOVERCAPED THERAPEUTIC PROTEINS IN CROP CELLS TO CERTAIN CELL TYPES FOR THE TREATMENT OF DISEASES